Genetic Disorders Drug Featured at Third Annual Congress of Myology

PTC Therapeutics, Inc. announced that PTC124, the company’s orally delivered investigational new drug for the treatment of genetic disorders due to nonsense mutations, was featured in a symposium at Myology 2008, the Third Annual Congress of Myology, on Friday, May 30 in Marseilles.
Fox Business